REFERENCES
- Nunery WR. Ophthalmic Graves’ disease: a dual theory of pathogenesis. Ophthalmol Clin North Am 1991;4:73–87
- Nunery WR, Martin RT, Heinz GW, Gavin TJ. The association of cigarette smoking with clinical subtypes of ophthalmic Graves' disease. Ophthal Plast Reconst Surg 1993;9:77–82
- Nunery WR, Nunery CW, Martin RT, et al. The risk of diplopia following orbital floor and medial wall decompression in subtypes of ophthalmic Graves' disease. Ophthal Plast Reconstruct Surg 1997;13:153–160
- Sokol JA, Foulks GN, Haider A, Nunery WR. Ocular surface effects of thyroid disease. Ocular Surf 2010;8:29–39
- Hiromatsu Y, Kaku H, Miyake I, et al. Role of cytokines in the pathogenesis of thyroid-associated ophthalmopathy. Thyroid: off J Amer Thyr Asso 2002;12:217–221
- Hiromatsu Y, Yang D, Bednarczuk T, et al. Cytokine profiles in eye muscle tissue and orbital fat tissue from patients with thyroid-associated ophthalmopathy. J Clin Endocrinol Metabol 2000;85:1194–1199
- Rozen S, Skaletsky H. Primer3 on the WWW for general users and for biologist programmers. Meth Molecul Biol 2000;132:365–386
- Kuriyan AE, Woeller CF, O'Loughlin CW, et al. Orbital fibroblasts from thyroid eye disease patients differ in proliferative and adipogenic responses depending on disease subtype. Investigat Ophthalmol Vis Sci 2013;54:7370–7377
- Koumas L, Smith TJ, Feldon S, et al. Thy-1 expression in human fibroblast subsets defines myofibroblastic or lipofibroblastic phenotypes. Amer J Pathol 2003;163:1291–1300
- Salvi M, Pedrazzoni M, Girasole G, et al. Serum concentrations of proinflammatory cytokines in Graves' disease: effect of treatment, thyroid function, ophthalmopathy and cigarette smoking. Euro J Endocrinol 2000;143:197–202
- Liu YH, Chen RH, Wu HH, et al. Association of interleukin-1beta (IL1B) polymorphisms with Graves' ophthalmopathy in Taiwan Chinese patients. Invest Ophthalmol Vis Sci 2010;51:6238–6246
- Khalilzadeh O, Anvari M, Esteghamati A, et al. Genetic susceptibility to Graves' ophthalmopathy: the role of polymorphisms in anti-inflammatory cytokine genes. Ophthal Genet 2010;31:215–220
- Wakelkamp IM, Bakker O, Baldeschi L, et al. TSH-R expression and cytokine profile in orbital tissue of active vs. inactive Graves' ophthalmopathy patients. Clin Endocrinol 2003;58:280–287
- Lacka K, Manuszewska E, Korczowska I, Lacki JK. The effect of methylprednisolone pulse treatment on cytokine network in Graves ophthalmopathy. Curr Eye Res 2007;32:291–297
- Cap J, et al. Plasma filtration in the treatment of Graves' ophthalmopathy: a randomized study. J Clin Apher 2010;25:209–215
- Xia N, Zhou S, Liang Y, et al. CD4+ T cells and the Th1/Th2 imbalance are implicated in the pathogenesis of Graves' ophthalmopathy. Inter J Mol Med 2006;17:911–916
- de Carli M, D'Elios MM, Mariotti S, et al. Cytolytic T cells with Th1-like cytokine profile predominate in retroorbital lymphocytic infiltrates of Graves' ophthalmopathy. J Clin Endocrinol Metabol 1993;77:1120–1124
- Yang D, Hiromatsu Y, Hoshino T, et al. Dominant infiltration of T(H)1-type CD4+ T cells at the retrobulbar space of patients with thyroid-associated ophthalmopathy. Thyroid 1999;9:305–310
- Kim SE, Yoon JS, Kim KH, Lee SY. Increased serum interleukin-17 in Graves' ophthalmopathy. Graefe's Arch Clin Exper Ophthalmol 2012;250:1521–1526
- Zhu C, Ma J, Liu Y, et al. Increased frequency of follicular helper T cells in patients with autoimmune thyroid disease. J Clin Endocrinol Metabol 2012;97:943–950
- Chen B, Tsui S, Smith TJ. IL-1 beta induces IL-6 expression in human orbital fibroblasts: identification of an anatomic-site specific phenotypic attribute relevant to thyroid-associated ophthalmopathy. J Immunol 2005;175:1310–1319
- Hwang CJ, Afifiyan N, Sand D, et al. Orbital fibroblasts from patients with thyroid-associated ophthalmopathy overexpress CD40: CD154 hyperinduces IL-6, IL-8, and MCP-1. Investigat Ophthalmol Vis Sci 2009;50:2262–2268
- Kumar S, Bahn RS. Relative overexpression of macrophage-derived cytokines in orbital adipose tissue from patients with graves' ophthalmopathy. J Clin Endocrinol Metabol 2003;88:4246–4250